Major companies operating in the fibrin sealants market are developing hemostatic agents designed to rapidly stop bleeding upon contact. Hemostatic agents are substances used to promote blood ...
The authors reviewed 11 randomized trials in which 328 patients were randomized to either receive or not receive fibrin sealant treatment after breast cancer surgery. End points included seroma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback